Abstract 5129
Background
Describe adherence patterns to the medical control processes derived from belonging to a CG situation in a sample of patients in CG situation for hereditary breast and ovarian cancer (CMOH), and its consequences with Psychological Wellbeing.
Methods
Descriptive cross-sectional descriptive study. Participants: Women carriers of high penetrance genes for breast and ovarian cancer (BRCA1 / 2), during the months of July 2012 to May 2014 who continue to control the Hereditary Cancer program of the Català Oncología Institute. 176 women. For the adhesion assessment, 3 asdoca questions were asked, based on recommendations and guidelines, the scale of the psychological well-being (BP) of Ryff was used, validated in the Spanish population.
Results
Regarding breast autoexploration, 58.6% of the patients did not follow the correct follow-up (either by hypervigilance or hypovigilance). Regarding the follow-ups in mammographic controls, 51.4% of the patients do the correct follow-up. When analyzing the relationship between breast self-exploration and the dimensions of psychological well-being, no statistically significant differences were found in any case, the same happens with mammographic controls Regarding the follow-up by MRI, 51.4% of the patients follow the correct one. A relationship is found in the dimension of Autonomy and Purpose in life.
Conclusions
The literature reports that there are well-defined and structured medical treatment protocols that allow monitoring of the carrier patients and that these are understandable to them with the final objective that patients have strategies to manage the situation without uncertainty (Ringwald et al., 2016). One possible explanation is that patients do not fully understand the protocols or that there are other personality variables that are modulating this aspect, such as a passive coping style or a high perception of risk (Den Heijer et al., 2013; Gopie et al., 2012). Conclusions Our population, approximately 50% of patients do not adhere to the proposed follow-up measures.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Melinda Gonzalez Concepcion.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
5603 - Development of a comprehensive next-generation targeted sequencing assay for detection of gene-fusions in solid tumors
Presenter: Vinay Mittal
Session: Poster Display session 3
Resources:
Abstract
4952 - Next-generation sequencing for better treatment strategy of cancer of unknown primary (CUP)
Presenter: Kang Kook Lee
Session: Poster Display session 3
Resources:
Abstract
4590 - Circulating-free DNA analysis from long-term surviving metastatic colorectal cancer patients undergoing surgery for resectable disease.
Presenter: Michele Ghidini
Session: Poster Display session 3
Resources:
Abstract
3696 - Ultra-sensitive detection of circulating tumor DNA identifies patients in high risk of recurrence in early stages melanoma
Presenter: Filip Janku
Session: Poster Display session 3
Resources:
Abstract
4295 - Identification of the founder BRCA1 mutation c.4117G>T (p.Glu1373*) recurring in Abruzzo and Lazio regions of Central Italy and predisposing to breast/ovarian and BRCA1-related cancers
Presenter: Daniela Di Giacomo
Session: Poster Display session 3
Resources:
Abstract
2214 - Enzalutamide (ENZA) and Apalutamide (APA) In vitro chemical reactivity studies and Activity in a Mouse Drug Allergy Model (MDAM)
Presenter: Mausumee Guha
Session: Poster Display session 3
Resources:
Abstract
5044 - Influence of genetic variation in COMT on cisplatin-induced nephrotoxicity in cancer patients.
Presenter: Bram Agema
Session: Poster Display session 3
Resources:
Abstract
3293 - Cardioprotective and anti-inflammatory effects of Empagliflozin during treatment with Doxorubicin: a cellular and preclinical study
Presenter: Vincenzo Quagliariello
Session: Poster Display session 3
Resources:
Abstract
3324 - Breast Cancer Organoids Model Treatment Response of HER2 Targeted Therapy in HER2-mutant Breast Cancer
Presenter: Xuelu Li
Session: Poster Display session 3
Resources:
Abstract
2115 - Preclinical in vivo screening to predict responder patients depend on EGFR status
Presenter: Yejin Kim
Session: Poster Display session 3
Resources:
Abstract